Navigation Links
Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
Date:9/10/2009

tatements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Sept. 9, 2009 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnership
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
2. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
3. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
4. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
7. Medarex to Receive Milestone Payment from Amgen
8. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
9. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
10. Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
11. July 2009 Mayo Clinic Womens HealthSource Highlights Food Storage Safety, Energy Therapies and Vitamins and Minerals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... DIEGO , Sept. 2, 2014  Volcano ... company focused on improving patient and economic outcomes ... innovative minimally invasive coronary and peripheral visualization, physiology ... be participating in the Morgan Stanley Healthcare conference ... by Scott Huennekens , president and chief ...
(Date:9/2/2014)... Sept. 2, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... products marketed as XIAFLEX ® in the U.S. and ... President, Tom Wegman , will present at the following ... Rodman & Renshaw 16 th Annual ... Tuesday, September 9, 2014 at 9:10 a.m. EDT ...
(Date:9/2/2014)... , September 2, 2014 ... NASDAQ: EMITF ) announced today following the ... Technologies Ltd. ("Elbit Medical") (TASE: EMTC-M), a subsidiary of ... a fully diluted basis, announced that on September 1, ... approximately 30.8% of the voting power ("Gamida Cell") and ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2Elbit Imaging Announces Gamida Cell Closed Option and Investment Agreements with a Major Pharmaceutical Company 2Elbit Imaging Announces Gamida Cell Closed Option and Investment Agreements with a Major Pharmaceutical Company 3
... Phase IIa Trial Increase in Dendritic, ... BASKING RIDGE, N.J., Oct. 10 VioQuest,Pharmaceuticals ... company focused on acquiring, developing and,commercializing targeted ... enrollment in its Phase I open-label dose ...
... New Phase 3 Plan Could Expedite Clinical Development Pathway, ... (Nasdaq: ANSV ) today announced that it will ... Adlea(TM) -- one of which has already,been planned in ... in,bunionectomy surgeries -- for a broad product label of ...
Cached Medicine Technology:VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM) 2VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM) 3VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM) 4Anesiva Defines Regulatory Pathway for Adlea with FDA 2Anesiva Defines Regulatory Pathway for Adlea with FDA 3Anesiva Defines Regulatory Pathway for Adlea with FDA 4Anesiva Defines Regulatory Pathway for Adlea with FDA 5
(Date:9/2/2014)... (HealthDay News) -- The quality of Americans, diets has ... between the rich and poor is growing, a new ... evidence to date that the extensive efforts by many ... having some payoff, but it also indicates that these ... a doctoral student in the department of nutrition at ...
(Date:9/2/2014)... Amy Norton HealthDay ... For people who want to lose weight and boost their ... trimming dietary fat, a new study suggests. In a ... assigned to follow a low-carbohydrate diet lost more weight over ... They also had bigger improvements in their cholesterol and triglyceride ...
(Date:9/2/2014)... 02, 2014 The Jerry Segal Classic ... on September 19 at The ACE Club and Green ... past 25 years, the Classic, organized by the Friends ... for programs and services designed to support patients and ... , “The Segal Classic is a labor of ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 North ... America Resectoscopes Market Outlook to 2020? provides key ... The report provides value, in millions of US ... US dollars) within market segments –, ... (Disposable and Reusable) Electrodes and Bipolar (Disposable and ...
(Date:9/2/2014)... Ohio (PRWEB) September 02, 2014 Humility of ... Home, Sept. 18 at St. Elizabeth Health Center, 1044 Belmont ... provides information about more than 200 common health problems as ... preventing illness and injury, and advice on when to seek ... a.m. to noon in the Youngstown Room; the evening session ...
Breaking Medicine News(10 mins):Health News:Quality of U.S. Diet Improves, Slightly 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 3Health News:The 25th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 3Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 4Health News:HMHP Offers ‘Health at Home’ Workshop 2
... Barcelona, Spain: An experimental drug that attacks cancer in ... advanced melanoma, delaying progression of the disease and prolonging ... (Wednesday) at the European Cancer Conference (ECCO 14) in ... to chemotherapy more than doubled the amount of time ...
... 26 Biomedtex Inc.,(Pink Sheets: PDNL.PK) ("Biomed" or ... that A. Marc Rocca, 42, will be,President and ... mission is to identify, evaluate and assess a ... and then,seek to capture and promote innovations with ...
... Nycomed Acquires Exclusive Rights Outside North America in Deal Valued ... ... N.J. and ZURICH, Switzerland, Sept. 26, NPS Pharmaceuticals, Inc. (Nasdaq: ... into a definitive agreement,which licenses to Nycomed the rights to ...
... research has yielded a clearer picture of which biomarkers ... colon cancer, bringing closer the day when patients who ... those that will, get the more aggressive treatment they ... doctors plan treatment of colon cancer chiefly by staging ...
... work investigating the reproducibility of glycemic index values, ... Research Center on Aging at Tufts University (USDA ... determinations (measure of the rate of glucose absorption ... white bread, resulted in a relatively high level ...
... to Home and the ... ... pioneer and largest provider of retail-,based health care in the United ... stores in Southeastern,Pennsylvania and Southern New Jersey. MinuteClinic plans to open ...
Cached Medicine News:Health News:New type of drug shows promise in attacking melanoma in an innovative way 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 3Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 4Health News:Study makes progress in zoning in on biomarkers for better colon cancer treatment 2Health News:Glycemic index values are variable, report researchers 2Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Philadelphia Metro Area 2Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Philadelphia Metro Area 3Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Philadelphia Metro Area 4Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Philadelphia Metro Area 5
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: